Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.

Authors
Seung, KJ
Khan, P
Franke, MF
Ahmed, S
Aiylchiev, S
Alam, M
Putri, FA
Bastard, M
Docteur, W
Gottlieb, G
Issue Date
2019-11-02
Submitted date
2020-01-15

Metadata
Show full item record
Journal
Clinical Infectious Diseases
Abstract
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.
Publisher
Oxford University Press
URI
http://hdl.handle.net/10144/619569
DOI
10.1093/cid/ciz1084
PubMed ID
31676905
Language
en
Description
We regret that this article is behind a paywall.
ISSN
1537-6591
Collections
TB